A Phase 2, Randomized, Double-Masked, Controlled, Proof-of-Concept Study to Evaluate the Safety and Biological Activity of a Water-free Tacrolimus Ophthalmic Solution (NOV05) for the Treatment of Non-Infectious Anterior Uveitis
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Be ≥18 years of age;
• Provide written informed consent;
• Be diagnosed with active non-infectious anterior uveitis requiring initiation or increase of topical steroids administration for the management of ocular inflammation;
• Have an onset of symptoms within 4 weeks;
Locations
United States
Massachusetts
Massachusetts Eye Research and Surgery Institution
RECRUITING
Waltham
New Jersey
Metropolitan Eye Research and Surgery Institute
RECRUITING
Palisades Park
Texas
Valley Retina Institute, P.A.
RECRUITING
Mcallen
Virginia
Virginia Eye Consultants
RECRUITING
Norfolk
Contact Information
Primary
Alice Meides, PhD
ameides@novaliq.com
+49 622150259
Time Frame
Start Date: 2026-03-16
Estimated Completion Date: 2026-10
Participants
Target number of participants: 20
Treatments
Active_comparator: Tacrolimus ophthalmic solution (high dose)
Active_comparator: Tacrolimus ophthalmic solution (low dose)
Related Therapeutic Areas
Sponsors
Leads: Novaliq GmbH